Navigate Fool.com
Will CUR beat
the market?

Neuralstem Inc. (NYSEMKT: CUR)

Community Rating: 3 Stars: Appealing

3.21 -0.04 (-1.23%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.22
Previous Close $3.25
Daily Range $3.16 - $3.24
52-Week Range $1.30 - $4.81
Market Cap $278.5M
P/E Ratio -10.48
Dividend (Yield) $0.00 (0.0%)
Volume 167,984
Average Daily Volume 1,072,300
Current FY EPS -$0.26

How do you think CUR
will perform against the market?

Top CUR Bull/Bear Pitches


kzachmann (0)
Submitted December 13, 2012

The small molecules developed by CUR attack disease at the point of origin rather than just mitigation of symptoms. Eventually, once the science fine tunes the delivery system and the molecule targeti … More

0 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted January 10, 2014

Along with pretty much everything else in the biopharma sector, stem cell companies are back in vogue. However, unless you believe that Athersys, Neuralstem, Neostem, and Pluristem have all simultaneo … More

0 Replies Reply Report this Post

News & Commentary

Biggest Biotech Clinical Wins of the Week

Find out which companies got the best clinical results for the week ending March 28, 2014.

Wednesday Sector Laggards: Drugs, Biotechnology Stocks

Why Neuralstem Inc. Shares Soared

Neuralstem shares jumped after reporting another positive study involving its lead pipeline product, NSI-566, in rats. Can shares head even higher?

Why Neuralstem Inc. Shares Spiked Higher

Neuralstem soars after publishing its final phase 1 data for NSI-566. Should shareholders be cheering or jeering this news?

Healthcare Sector Slightly Higher Near Bell; Neuralstem Gains After Pricing $4-Mln Private Offering

Sector Update: Healthcare

Spot Tenbagger Discovery Potential in Biotech: Michael Berry

Cloning: A Stem Cell Revolution?

Will the creation of cloned human stem cells create a treatment revolution and a profitable investment?

This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.

FDA OKs Neuralstem Trial Treating Spinal Cord Injuries With Stem Cells

NSI-566 has already shown promise in ALS and rat models of spinal cord injuries.

See More CUR News...





Neuralstem Inc. (CUR) Description

Neuralstem Inc is an biotechnology company which is engaged on developing and commercializing human neural stem cell technology in the emerging field of regenerative medicine. Website: http://www.neuralstem.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks